← Leaderboards
Joshua E. Allen
Oncoceutics, Inc.
$2,775,850
Attributed
$2,775,850
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2019–20$2M$1.5M$1M$500K$0
'19
'20
Funding mix
By agency
NIH$2,775,850 · 2
By mechanism
R44$2,775,850 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Enrollment”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$54,781,680
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnrollmentInvestigationDoseEfficacy EvaluationCohortG-Protein-Coupled ReceptorsAdvanced Malignant NeoplasmDopamine ReceptorDrug KineticsEffective TherapyClinical TrialsAntagonist GExhibitsFirst-In-HumanBiologicalAnticancer ActivityApoptosisBloodAdverse EventClinical EfficacyCancer TherapyCancer PatientBaseIn Vitro
Grant awards (3)
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma$999,250
R44 · FY2020 · CA · contact PI
Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma$999,600
R44 · FY2019 · CA · contact PI
Clinical Efficacy Evaluation of First-in-class Imipridone ONC201 in Recurrent Type II Endometrial Cancer$777,000
R44 · FY2019 · CA · contact PI